CR20190567A - Derivados de indol n-sustituidos - Google Patents

Derivados de indol n-sustituidos

Info

Publication number
CR20190567A
CR20190567A CR20190567A CR20190567A CR20190567A CR 20190567 A CR20190567 A CR 20190567A CR 20190567 A CR20190567 A CR 20190567A CR 20190567 A CR20190567 A CR 20190567A CR 20190567 A CR20190567 A CR 20190567A
Authority
CR
Costa Rica
Prior art keywords
indole derivatives
substituted indole
formula
derivatives
prostaglandin
Prior art date
Application number
CR20190567A
Other languages
English (en)
Inventor
Sylvia Richard-Bildstein
Isabelle Lyother
Heinz Fretz
Thierry Sifferlen
Julien Pothier
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CR20190567A publication Critical patent/CR20190567A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con derivados de la fórmula (I) Fórmula (I) donde R1, y R2 son como se los describe en la memoria, con su preparación, con sales farmacéuticamente aceptables de los mismos, y con su uso como productos farmacéuticos, con composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I), y especialmente con su uso como moduladores del receptor EP2 de la prostaglandina 2.
CR20190567A 2017-05-18 2018-05-17 Derivados de indol n-sustituidos CR20190567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017062008 2017-05-18
PCT/EP2018/062865 WO2018210995A1 (en) 2017-05-18 2018-05-17 N-substituted indole derivatives

Publications (1)

Publication Number Publication Date
CR20190567A true CR20190567A (es) 2020-02-10

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190567A CR20190567A (es) 2017-05-18 2018-05-17 Derivados de indol n-sustituidos

Country Status (32)

Country Link
US (2) US20200069686A1 (es)
EP (1) EP3625224B1 (es)
JP (1) JP7065117B2 (es)
KR (1) KR102650756B1 (es)
CN (1) CN110621666A (es)
AR (1) AR111806A1 (es)
AU (1) AU2018269667B2 (es)
BR (1) BR112019024114A2 (es)
CA (1) CA3063637A1 (es)
CL (1) CL2019003257A1 (es)
CO (1) CO2019010804A2 (es)
CR (1) CR20190567A (es)
CY (1) CY1124528T1 (es)
DK (1) DK3625224T3 (es)
EA (1) EA039630B1 (es)
ES (1) ES2894124T3 (es)
HR (1) HRP20211532T1 (es)
HU (1) HUE056406T2 (es)
IL (1) IL270616B (es)
LT (1) LT3625224T (es)
MA (1) MA49127B1 (es)
MX (1) MX2019013639A (es)
PE (1) PE20191787A1 (es)
PH (1) PH12019502562A1 (es)
PL (1) PL3625224T3 (es)
PT (1) PT3625224T (es)
RS (1) RS62441B1 (es)
SG (1) SG11201908660RA (es)
SI (1) SI3625224T1 (es)
TW (1) TWI768043B (es)
UA (1) UA124748C2 (es)
WO (1) WO2018210995A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1267867T3 (da) 2000-03-24 2008-08-25 Asterand Uk Ltd Anvendelse af prostanoid-EP4-receptorantagonister til behandling af hovedpine og assays til sådanne antagonister
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
EP1494667A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
BR0311247A (pt) 2002-05-23 2005-03-15 Theratechnologies Inc Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2
ATE396182T1 (de) 2003-01-29 2008-06-15 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
EP1661897B1 (en) * 2003-08-26 2013-12-04 Teijin Pharma Limited Pyrrolopyrimidinone derivative
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EA200601830A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
KR20070006891A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1885722B1 (en) 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
EP2013169B1 (en) 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2008006583A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
AU2008221194B2 (en) 2007-02-26 2013-06-27 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
US8003661B2 (en) 2007-03-26 2011-08-23 Merck Canada Inc. Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
CA2724077C (en) 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
GB2474813B (en) 2008-09-19 2014-05-28 Biotechnology Res Corp Ltd Triterpenoid compounds and methods of use thereof
EP2346866B1 (en) 2008-09-25 2013-11-27 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition
KR101857310B1 (ko) 2010-09-29 2018-05-11 가부시키가이샤 에누비 켄코우겡큐쇼 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
US8828987B2 (en) 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
WO2012127032A1 (en) * 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
ES2559513T3 (es) 2011-07-04 2016-02-12 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas del receptor EP4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
RU2638540C1 (ru) 2012-04-24 2017-12-14 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
US9593081B2 (en) 2013-06-12 2017-03-14 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
KR102276644B1 (ko) 2013-09-04 2021-07-13 브리스톨-마이어스 스큅 컴퍼니 면역조절제로서 유용한 화합물
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CA2927392C (en) 2013-10-17 2021-11-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2015094912A1 (en) 2013-12-17 2015-06-25 Eli Lilly And Company Dimethylbenzoic acid compounds
HUE035698T2 (en) 2013-12-17 2018-05-28 Lilly Co Eli Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
CN106572993B (zh) 2014-05-23 2019-07-16 卫材R&D管理有限公司 Ep4拮抗剂在制备治疗癌症的药物中的应用
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
KR102559499B1 (ko) 2015-01-09 2023-07-25 오노 야꾸힝 고교 가부시키가이샤 삼환성 스피로 화합물
CA2993312A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
JP6860559B2 (ja) 2015-10-16 2021-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｅｐ４アンタゴニスト

Also Published As

Publication number Publication date
IL270616B (en) 2022-01-01
WO2018210995A1 (en) 2018-11-22
PH12019502562A1 (en) 2020-07-20
SG11201908660RA (en) 2019-10-30
PE20191787A1 (es) 2019-12-24
MA49127A (fr) 2021-05-26
KR102650756B1 (ko) 2024-03-22
AU2018269667A1 (en) 2019-10-24
US20200069686A1 (en) 2020-03-05
DK3625224T3 (da) 2021-11-08
EP3625224A1 (en) 2020-03-25
MX2019013639A (es) 2020-01-21
HRP20211532T1 (hr) 2022-01-07
LT3625224T (lt) 2021-10-25
UA124748C2 (uk) 2021-11-10
CA3063637A1 (en) 2018-11-22
CN110621666A (zh) 2019-12-27
JP7065117B2 (ja) 2022-05-11
US20230165859A1 (en) 2023-06-01
SI3625224T1 (sl) 2021-11-30
KR20200006589A (ko) 2020-01-20
TW201900637A (zh) 2019-01-01
ES2894124T3 (es) 2022-02-11
EA039630B1 (ru) 2022-02-18
BR112019024114A2 (pt) 2020-06-02
JP2020520359A (ja) 2020-07-09
EP3625224B1 (en) 2021-08-04
HUE056406T2 (hu) 2022-02-28
TWI768043B (zh) 2022-06-21
AU2018269667B2 (en) 2022-02-03
CY1124528T1 (el) 2022-07-22
CO2019010804A2 (es) 2019-10-09
EA201992679A1 (ru) 2020-05-06
PT3625224T (pt) 2021-10-06
AR111806A1 (es) 2019-08-21
RS62441B1 (sr) 2021-11-30
CL2019003257A1 (es) 2020-03-27
PL3625224T3 (pl) 2022-01-10
MA49127B1 (fr) 2022-05-31

Similar Documents

Publication Publication Date Title
PH12019502562A1 (en) N-substituted indole derivatives
MY195888A (en) N-Substituted Indole Derivatives As Pge2 Receptor Modulators
MX2021004000A (es) Derivados de piperidina.
MY169986A (en) Benzimidazole-proline derivatives
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
PH12015502632A1 (en) Cxcr7 receptor modulators
MX2019013718A (es) Derivados de pirimidina como moduladores del receptor de pge2.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
PH12019501724A1 (en) Estrogen receptor modulators
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
MX2021015727A (es) Derivados de piridin-3-ilo.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
NZ775905A (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators